|
Laboratory
For Cerebrovascular Biophysics Cerebral Vasospasm Studies
Research
in Cerbral Vasospasm 
Dr Peterson's
Labs - Studies in Protein Kinase C (PKC).
Dr Zervas's
Lab - PET Imaging
of CBF, CBV, O2M, OEF and GluMetab Images
courtesy of Anna-Liisa
Brownell, PhD in collaboration on a study of CNS tissue metabolism (rGMR,
rCMRO2, rOEF, rCBF, rCBV) during cerebral vasospasm. (For
more info.) 
Functional
CT Studies Images courtesy
of CIPR (Center for Imaging and
Pharmaceutical Research) as part of a collaboration with the CNS
project group. The images are the work of George
Hunter, MD and Leena
Hamberg, PhD as part of a study on peripheral tissue perfusion (CBV, TTT,
CBFi) during cerebral vasospasm. (For
more info.)
Dr Zervas's
& Dr
Peterson's Labs - Studies in laser-induced
pulsed-fluid wave treatment of vasospastic cerebral arteries.
MGH
Laser Center
|
Cerebral vasospasm after subarachnoid hemorrhage leads to mortality and disability
in a large number of patients annually. The basic mechanisms by which adventitial
blood clot produces chronic cerebral arterial constriction are not well understood;
consequently, therapy has been only partially effective. The main research goal
then has been to isolate and define those processes most important to the development
of this pathology, so that truly effective pharmacological intervention can be
devised. Previous studies in
the laboratory have shown that the erythrocyte component of subarachnoid blood
is essential to the process. Lysis of those erythrocytes and release of vasoactive
hemoglobin is a potent contributor. In vitro studies of human and animal erythrocytes
have shown that these cells, which incubated under conditions which mimic subarachnoid
blood clot, become immunologically reactive: activating the complement protein
cascade leading ultimately to formation of "membrane attack complex"
and erythrocyte lysis. Other effects of complement activation include stimulation
of inflammation (which additionally contributes significantly to vasoconstriction)
and increased vascular permeability (which acts to reinforce the cycle by admitting
increased amounts of complement protein).
The laboratory is currently purifying various complement factors in our animal
model and using radiolabelled materials to monitor movement into and accumulation
in the subarachnoid clot (in particular C5, C8 and C9). The laboratory plans then
to produce specific antibodies against these factors to observe the effect of
specific decomplementation on the development of cerebrovascular constriction
and perivascular inflammation.
Other studies in our laboratory focus on the specific mechanisms which activate
smooth muscle contraction in cerebral arteries. Early studies suggest that agonists
which activate long-lasting constriction may work though the diacylglycerol (DAG)-activated
protein kinase C (PKC) system. Using in vitro methods we are studying DAG levels
and PKC activity in cerebral vessels and the connection between these factors
and the long lasting vasoconstriction which is the hallmark pathology of cerebral
vasospasm. In particular, we hope to clarify the extent to which the vasoactivity
of hemoglobin is expressed through this system.
|
| Neurosurgery
Clinical Units | | |